AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation
Program Code: SCF-CF-S9-0001
Development Status: Hit Discovery & Scaffold Architecture Phase
Objective:
Identify chemically tractable scaffold families capable of achieving the Target Product Profile established in Stages 1–8 while maintaining compatibility with inhaled pulmonary delivery.
IMPORTANT DEVELOPMENT BOUNDARY
At Stage 9, no actual drug candidate has been discovered.
This phase generates:
- Hit identification strategy
- Scaffold hypotheses
- SAR hypotheses
- Screening architecture
- Candidate prioritization framework
It does not generate validated drug structures, efficacy claims, or clinical candidates.
I. REVERSE-ENGINEERED TARGET REQUIREMENTS
Desired Biological Profile
Requirement | Priority |
Partial elastase modulation | Critical |
Pulmonary retention | Critical |
Low systemic exposure | Critical |
Protease selectivity | Critical |
Inhalation compatibility | Critical |
Chronic-use safety | Critical |
II. ELASTASE TARGET ANALYSIS
Target
Human Neutrophil Elastase (HNE)
Protein Family
Serine Protease
Therapeutic Challenge
Many historical elastase inhibitors failed because of:
- inadequate lung exposure
- poor selectivity
- excessive systemic inhibition
- unfavorable PK
SCF strategy therefore focuses on:
Localized Regulatory Modulation
rather than complete catalytic shutdown.
III. HIT IDENTIFICATION DOMAINS
Domain A
Direct Elastase-Binding Scaffolds
Objective:
Interact with elastase catalytic machinery while maintaining selectivity.
Domain B
Allosteric Regulatory Scaffolds
Objective:
Modulate enzyme activity without complete inhibition.
Advantages:
- improved safety
- preservation of host defense
- lower resistance pressure
Domain C
Protease Network Stabilizers
Objective:
Normalize elastase–MMP signaling balance.
Advantages:
- broader disease modification
- ECM preservation
IV. PRIMARY SCAFFOLD FAMILIES
Scaffold Family A
Taspine-Inspired Polycyclic Heterocycles
Source Logic:
Croton lechleri
Desired Features:
- tissue-preservation signaling
- cytokine modulation
- scaffold diversification potential
Development Rating
Very High
Scaffold Family B
Iridoid-Inspired Bicyclic Scaffolds
Source Logic:
Himatanthus sucuuba
Desired Features:
- inflammatory harmonization
- favorable safety profile
- inhalation-compatible molecular size
Development Rating
High
Scaffold Family C
Oxindole-Derived Heterocycles
Source Logic:
Uncaria tomentosa
Desired Features:
- immune modulation
- established medicinal chemistry tractability
Development Rating
High
Scaffold Family D
Non-Botanical Elastase Regulatory Chemotypes
Source Logic:
Target-driven medicinal chemistry
Desired Features:
- direct elastase interaction
- optimized PK
- maximal selectivity
Development Rating
Very High
V. PRELIMINARY SCAFFOLD MATRIX
Scaffold Family | Target Fit | PK Fit | Safety Fit | Manufacturability |
Taspine-inspired | High | Moderate | High | Moderate |
Iridoid-inspired | Moderate | High | High | High |
Oxindole-derived | High | Moderate | Moderate–High | High |
Target-driven synthetic | Very High | High | Variable | High |
VI. SAR HYPOTHESIS GENERATION
Scaffold Optimization Goals
Goal 1
Increase pulmonary retention.
Methods:
- polarity balancing
- inhalation-compatible physicochemistry
Goal 2
Reduce systemic exposure.
Methods:
- permeability tuning
- lung-targeted disposition
Goal 3
Increase elastase selectivity.
Methods:
- active-site complementarity
- allosteric modulation exploration
Goal 4
Preserve host defense.
Methods:
- partial modulation
- exposure-controlled pharmacology
VII. HIT SCREENING CASCADE
Tier 1 — Computational Prioritization
Endpoints:
- physicochemical profile
- inhalation suitability
- novelty assessment
Tier 2 — Biochemical Screening
Endpoints:
- elastase modulation
- selectivity panel
Comparators:
- Proteinase 3
- Cathepsin G
- Trypsin
- Chymotrypsin
Tier 3 — Cellular Screening
Models:
CF airway epithelial cultures
Endpoints:
- IL-8
- MMP-9
- epithelial integrity
- cytotoxicity
Tier 4 — Functional CF Models
Endpoints:
- elastin degradation
- ECM preservation
- inflammatory modulation
VIII. HIT TRIAGE CRITERIA
Advancement Thresholds
Criterion | Requirement |
Elastase modulation | Demonstrated |
Selectivity | Favorable |
Cytotoxicity | Acceptable |
Pulmonary compatibility | Acceptable |
Synthetic tractability | Acceptable |
IP differentiation | Favorable |
IX. SCF HIT CLUSTERS
Cluster Alpha
Taspine-Inspired Regulatory Series
Purpose:
Tissue-protective elastase modulation.
Priority:
Tier 1
Cluster Beta
Iridoid Regulatory Series
Purpose:
Inflammatory harmonization.
Priority:
Tier 2
Cluster Gamma
Oxindole Regulatory Series
Purpose:
Immune-compatible protease modulation.
Priority:
Tier 2
Cluster Delta
Synthetic Elastase Regulatory Series
Purpose:
Primary candidate generation.
Priority:
Tier 1
X. CANDIDATE GENERATION STRATEGY
Wave 1
50–100 virtual scaffold variants
↓
Wave 2
10–20 prioritized chemotypes
↓
Wave 3
3–5 optimized lead series
↓
Wave 4
1–2 preclinical development candidates
XI. STAGE 9 DECISION
Lead Scaffold Prioritization
Priority 1
Synthetic elastase-regulatory chemotypes
Priority 2
Taspine-inspired scaffold family
Priority 3
Iridoid-inspired scaffold family
Priority 4
Oxindole-derived scaffold family
STAGE 9 OUTCOME
READY FOR STAGE 10
STAGE 10 — LEAD SERIES DESIGN & MEDICINAL CHEMISTRY CAMPAIGN
Stage 10 will focus on:
- Defining specific scaffold cores.
- Building medicinal chemistry series.
- Establishing structure–activity relationships.
- Designing ADME optimization pathways.
- Creating candidate-selection algorithms.
- Generating FDA-aligned lead-optimization plans.
Because actual drug-design details can become highly technical and experimentally actionable, Stage 10 should remain at a conceptual medicinal-chemistry planning level until supported by laboratory screening and validation data.
MASTER REGISTRY INDEX
SCF-CF-S9-0001 — Hit Identification & Molecular Scaffold Engineering
SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator
SCF-HITDISC-0001 — Hit Discovery Framework
SCF-SAR-0001 — Structure–Activity Relationship Framework
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-API-DP-0001 — API Discovery Profile Framework
SCF-FDA-IND-0001 — Translational Development Framework